Analytical Data
-
Gene name
ABCC4
- Application
-
Alternative Names
ABC-C4; MRP4; MOATB; Canalicular Multispecific Organic Anion Transporter B; Multidrug Resistance-Associated Protein 4; Multi-specific organic anion transporter B
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O15439
-
Expression Region
Ile1041~Gln1274
-
Molecular Weight
30kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ABCC4, also known as Multidrug Resistance Protein 4 (MRP4), is a member of the ATP-binding cassette (ABC) transporter family, which plays a critical role in the cellular efflux of various compounds, including drugs, metabolites, and endogenous substances. Understanding ABCC4's function is crucial due to its implications in drug resistance, particularly in cancer therapy, where overexpression of this transporter can lead to decreased efficacy of chemotherapeutic agents. Research has shown that ABCC4 is involved in the transport of nucleotide analogs, which are pivotal in antiviral and anticancer strategies. Furthermore, its regulation is influenced by several factors, including transcriptional activity and post-translational modifications, making it an important target for therapeutic intervention. Recent studies have focused on the structural biology of ABCC4, aiming to elucidate its transport mechanisms and interactions with substrates. The recombinant expression of ABCC4 protein enables high-throughput studies, allowing researchers to assess its pharmacological properties and potential to mediate drug interactions. Investigating ABCC4's role and regulatory mechanisms can provide insights into overcoming drug resistance and improving treatment outcomes in cancer and viral infections. Understanding this transporter could lead to the development of novel strategies to modulate its activity, enhancing the effectiveness of existing therapies and potentially leading to new therapeutic avenues in personalized medicine.
